<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association and The European Association for the Study of <z:mp ids='MP_0002055'>Diabetes</z:mp> recommend <z:chebi fb="0" ids="6801">metformin</z:chebi> as the initial agent of choice in the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Unfortunately, most patients require multiple medications to obtain glycemic control </plain></SENT>
<SENT sid="2" pm="."><plain>One of the newest additions to the <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> armamentarium is the class of drugs known as dipeptidyl-peptidase IV (DPP-IV) inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>This novel approach focuses on harnessing the beneficial effects of GLP-1, an incretin hormone released from the gut postprandially </plain></SENT>
<SENT sid="4" pm="."><plain>The first DPP-IV inhibitor approved in the United States was <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>It has been studied in both monotherapy and combination therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Combination studies with <z:chebi fb="0" ids="6801">metformin</z:chebi> realize a <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c reduction of 0.65%-1.1% </plain></SENT>
<SENT sid="7" pm="."><plain>The combination of the two has a modest positive effect on body weight with the convenience of an oral route of administration </plain></SENT>
<SENT sid="8" pm="."><plain>It has also been shown to be highly tolerable, efficacious and with little risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>This review will focus on combination therapy with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> with emphasis on combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
</text></document>